Longevity News
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
Mitochondrial double-stranded RNA accumulates in the brain after midlife, with levels further elevated in Alzheimer's disease where they correlate with cognitive decline. This accumulation reflects disrupted RNA processing machinery and triggers chronic inflammatory signaling, establishing mitochondrial RNA homeostasis as a measurable driver of age-related neurodegeneration.
A proposed experiment using underground laboratory space would isolate the contribution of muon radiation to epigenetic aging by comparing cell cultures grown in radiation-depleted versus surface conditions. This addresses a fundamental gap in aging research: quantifying how much age-related damage stems from unavoidable external radiation versus internal biological processes.
A 18-year partnership between UCL and Eisai—extended through 2030—demonstrates that sustained institutional collaboration in neuroscience drug discovery outperforms the typical transactional model. Continuity in funding and leadership, rather than speed, may be essential for solving complex neurodegeneration problems like Alzheimer's and Parkinson's disease.
Haut.AI has launched an AI-powered platform that analyzes skin across the entire body—not just the face—to provide quantitative measurements and personalized product recommendations. The technology was trained on over 100,000 skin images across all skin types and validated for clinical accuracy, addressing a market gap where 80% of consumers report pressure to maintain healthy-looking skin.
DiamiR Biosciences will present three posters at the 2026 Alzheimer's Association International Conference focused on blood-based biomarkers for cognitive decline detection, including plasma APOE genotyping and circulating microRNA signatures. These biomarkers represent a shift toward non-invasive, early-stage identification of neurodegeneration risk before clinical symptoms manifest.
AI care robots demonstrated measurable reductions in loneliness and depressive symptoms among isolated older adults in South Korea, with effectiveness sustained over a 12-week intervention period. The mechanism appears to involve both direct companionship and the initiation of human social contact through robot-facilitated engagement.
A regulatory RNA molecule specific to immune T cells sustains metabolic balance and immune function in the aging liver, addressing a fundamental mechanism of age-related decline. This correction validates findings on how the body maintains coordinated immune and metabolic signaling during aging.
Sana Biotechnology's immune-evasive cell therapy (UP421) has demonstrated survival of transplanted insulin-producing cells without immunosuppressive medication in a first-in-human study, with transplanted cells responding dynamically to glucose levels after 14 months. This approach fundamentally reframes type 1 diabetes treatment from immune suppression to immune tolerance, with potential implications for regenerative medicine across multiple organ systems.
Theriva Biologics is testing a more frequent dosing schedule of VCN-01, an oncolytic virus therapy, combined with standard chemotherapy in newly diagnosed metastatic pancreatic cancer patients. The Phase 2a trial in Spain aims to establish feasibility and safety of three bimonthly doses, building on prior evidence of improved survival outcomes with the current two-dose regimen.
Helix and AstraZeneca established a multi-year partnership granting access to GenoSphere cohorts—genomic datasets paired with longitudinal clinical records spanning 13 years—to accelerate drug discovery across cardiometabolic, respiratory, and autoimmune conditions. This arrangement represents a shift toward precision-medicine-informed development pipelines that integrate genotype with documented clinical outcomes.
Insilico has initiated Phase III trials of Rentosertib, an oral TNIK inhibitor designed through AI-driven drug discovery, for idiopathic pulmonary fibrosis. The 52-week trial enrolling 320 patients will measure the drug's capacity to slow lung function decline, a primary determinant of IPF progression and mortality risk.
Annovis Bio has enrolled 850 patients with early Alzheimer's disease in a Phase 3 trial of Buntanetap, a daily oral therapeutic targeting pTau217 pathology. The dual-endpoint design will assess both symptomatic improvement at six months and disease-modifying effects at 18 months, with regulatory submissions anticipated in 2027-2028.